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As the world deals with a pandemic, there remains another global challenge that cannot be ignored. Use
of broad-spectrum antibiotics may be justified, as we are trying to treat a novel disease condition, which,
in turn, could lead to an increase in antimicrobial resistance. We can decrease morbidity, mortality, and
health care costs by controlling antimicrobial resistance, but it requires antimicrobial stewardship. Major
components of effective and timely antimicrobial stewardship are diagnostic stewardship, infection preven-
tion and control, and integration of COVID-19-specific flags into electronic health records, all of which
may be integrated into current strategies of COVID-19 mitigation and management. Going through the
influenza season of 2020, implementation of antimicrobial stewardship education efforts in the United
States can help us contend with influenza in addition to COVID-19 and any bacterial coinfections or sec-
ondary infections. Additional solutions include the development of vaccines, alternative therapies, such as
antibodies, and advanced diagnostics using advances in genomics and computer science.
INTRODUCTION
Research has shown that medical school students and
graduating pharmacy students desire more education on
the appropriate use of antimicrobials, a key component of
antimicrobial stewardship (AMS), which aims to resolve the
patient’s infection, minimize antimicrobial resistance, and
reduce toxicities associated with antimicrobial use (1, 2).
Per the Infectious Diseases Society of America (IDSA) and
the Society for Healthcare Epidemiology of America
(SHEA), the primary goal of AMS is to optimize clinical
outcomes for the patient and minimize consequences of
antimicrobial use, such as toxicities, selection for oppor-
tunistic pathogens such as Clostridioides difficile, and anti-
microbial resistance (3). An interprofessional curriculum
on AMS geared toward preclinical medical and pharmacy
students was shown to positively influence not only AMS
but also professional collaboration (4). Significantly more
students who participated in this curriculum could
describe the function of the medical and pharmacy pro-
fessions in appropriate antimicrobial use, communicate in
an interprofessional manner, and find ways to collaborate
with each other (4). Even though 65% of medical schools
in the United States teach AMS during preclinical years,
most of these schools have focused largely on didactic
lectures, with only a few offering opportunities for interpro-
fessional education in stewardship (5). There has not been an
overt request for AMS inclusion as part of preclinical educa-
tion. For instance, the 2015 IDSA Stewardship Commitments
for the White House Forum on Antibiotic Stewardship position
statement bypassed AMS education of health professions stu-
dents as one of its commitments (6). Guidelines by IDSA and
SHEA recommend that academic medical centers and teach-
ing hospitals integrate AMS education into their preclinical
and clinical curricula (7). This article highlights the challenges
of stewardship in the midst of a fluid and uncertain pandemic.
It reiterates the importance of education at all levels so that
future health care providers have good foundational knowl-
edge of AMS and integrate the principles in their future clini-
cal practice.
The use of broad-spectrum antibiotics as a component of
COVID-19 treatment may be justified when you consider the
overlap of some respiratory symptoms of bacterial commu-
nity-acquired pneumonia with that of COVID-19, such as
cough, fever, and shortness of breath. Compounding this issue
is the fact that the risk of COVID-19 severity and hospitaliza-
tions increase with age and/or presence of underlying medical
conditions, both of which are also risk factors for other infec-
tions (8).
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Prescribing antibiotics for a viral infection, even one
without a U.S. Food and Drug Administration-approved
standard of care, has to be considered in the context of
antimicrobial resistance. The current pandemic, with its
urgent need of treating a disease, the progression of which
is being scientifically investigated in real time, has the poten-
tial to increase antimicrobial resistance (9). The inappropri-
ate prescription of antibiotics despite the lack of evidence
of bacterial coinfections in patients with COVID-19 will
inevitably worsen antimicrobial resistance (10). More than
2.8 million antibiotic-resistant infections occur in the United
States each year, and more than 35,000 people die as a
result (11). At last count, which was in 2017, nearly 223,900
people in the United States required hospital care for the
opportunistic pathogen Clostridioides difficile, and at least
12,800 people died from this preventable infection (11). C.
difficile infections are caused by the same factors that drive
antibiotic resistance: antibiotic use and transmission of in-
fectious agents. The increase in resistant infections in the
community not only puts more people in the community at
risk of these infections but also makes transmission harder
to identify and contain, thereby threatening the progress
made to protect patients in health care (9). Antibiotic re-
sistance disproportionally impacts the young, elderly, and
sick, who are the most vulnerable individuals who receive
medical care often. However, technically anyone would be
at risk of infection with resistant pathogens. Infections with
drug-resistant pathogens are harder and more expensive to
treat and result in increased morbidity and mortality as well
as extended length of hospital stay (12). These resistant
pathogens spread from patient to patient within hospitals
and across health care facilities through patient transfer, and
they eventually spill over into communities, becoming much
harder to control (11). It may be a few years before we real-
ize the impact of the pandemic on the incidence of antibi-
otic-resistant infections. What is vital is our continued
effort to measure and improve how antimicrobials are pre-
scribed by clinicians and used by patients, which, in essence,
is AMS.
METHODS
To establish the significance of what we are proposing,
we have reviewed some of the noteworthy papers in antimi-
crobial resistance and AMS, such as the CDC report on
antimicrobial resistance, economist Jim O’Neill’s final report
to the United Kingdom government on tackling drug-resist-
ant infections globally, as well as the SHEA guidelines for
health care epidemiologists in U.S. acute-care hospitals. In
addition, we reviewed a few 2020 publications on AMS in
the midst of COVID-19 along with select publications on
the importance of diagnostic stewardship. Since we would
like all medical schools to include teachings on AMS princi-
ples, we also reviewed some of the important publications
discussing this topic. In addition, we have summarized some
of the challenges in upholding principles of stewardship in
the midst of seasonal influenza, past influenza pandemics,
and the current pandemic.
RESULTS
It is time to seriously think of AMS and revisit institu-
tional policies as we head into influenza season. A 2016
research study involving 322 patients hospitalized with influ-
enza revealed that most patients received antibiotics upon
admission, with more than one-third being inappropriately
continued on antibiotics despite a lack of evidence of bacte-
rial infection (13). Traditionally, there have not been any for-
mal recommendations for inclusion of AMS programs in dis-
aster planning or emergency preparedness efforts (14).
COVID-19 is underscoring the need to have AMS programs
integrated with hospital infection prevention programs (15).
A review of scientific literature describing clinical outcomes
of the 2009 pandemic influenza virus infection revealed sec-
ondary bacterial infection in almost 25% of severe or fatal
cases (16). There is a need to prospectively monitor coin-
fections in patients with COVID-19 to understand whether
coinfection affects disease progression and, at the same
time, enables AMS (17).
A major component of effective and timely AMS is diag-
nostic stewardship, which includes the process of ordering
and interpreting diagnostic tests before initiating or continu-
ing treatment (18). Interpretation of sensitive molecular
tests that detect multiple targets simultaneously or use of
next-generation sequencing tests that detect microbial
genomes must also take into account the pretest likelihoods
of infection with each target in the test (19). Use of rapid
diagnostics enables early diagnosis, leading to the use of tar-
geted antimicrobials and bypassing the misuse of empirical
antimicrobials. However, diagnosis has to be considered in
the context of colonization versus an actual infection, with
the latter being distinguished by the presence of disease-
causing microorganisms on or in the body of a patient and
the former being characterized by microbial presence with-
out disease (20). Hospitals have to continue efforts to dis-
tinguish between the two. For instance, laboratory policies
may enforce strict conditions of specimen collection and/or
handling before specimens are processed, thereby minimiz-
ing contamination with colonized microorganisms (19).
Tests may also be performed in a stepwise fashion, with sub-
sequent tests dependent on results from the previous tests
(19). Some hospitals provide ongoing education to their
clinicians about appropriate indications and sampling for
tests. A multidisciplinary expert panel of IDSA and SHEA rec-
ommended not relying solely on didactic educational materials
for stewardship and encouraged academic medical centers as
well as teaching hospitals to integrate AMS education into
their preclinical and clinical curricula (7). To achieve sustained
stewardship, education has to be combined with other AMS
efforts, like prospective audit and feedback (PAF), an external,
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expert review of antibiotic therapy with suggestions to opti-
mize use (7).
It is important to include the role of animals in our
AMS education efforts. Antimicrobial resistance is com-
pounded by the frequent and heavy use of antimicrobials in
our food animals, making animals a crucial player in the
spread and evolution of resistant pathogens (21). Even the
microbiota of wild animals is being acknowledged as a reser-
voir of resistance genes (21). Research has also shown that
reduction of antibiotic use in food animals is accompanied
by a reduction in antibiotic-resistant bacteria in animals as
well as in humans directly exposed to these animals (22).
Not surprisingly, timely, accurate diagnosis greatly increases
the likelihood of improving clinical care and patient health.
Proper diagnostic stewardship is a process that involves select-
ing the correct (or as nearly correct as possible) diagnostic test
for the appropriate patient with a certain clinical scenario, fol-
lowed by timely collection of the relevant clinical specimen, its
transport and processing, and timely reporting of test results
(23). However, ongoing evaluation and careful monitoring of
diagnostic stewardship is necessary, as overuse of some rapid
tests can increase health care costs without improving patient
care, while underuse may delay diagnosis and patient recovery
(18). Serving as an example of utilizing existing infrastructure to
meet the demands of AMS programs while managing COVID-
19, the Mayo Clinic modified its prospective audit system by
integrating two COVID-19-specific AMS program flags into
their electronic health records (EHRs) (24). The first AMS pro-
gram flag rule identified in-patients with a negative SARS-CoV-2
reverse transcription-PCR (RT-PCR) test within the last week
and who were already on COVID-19 medications, as indicated
by active therapy, which was hydroxychloroquine in this case.
The second AMS program flag rule identified laboratory-con-
firmed COVID-19 patients and triggered review by an
Infectious Diseases team. This second AMS program flag also
identified pending patients with an active therapy order, who, if
RT-PCR negative, reverted to the first flag rule and, if RT-PCR
positive, prompted review by the Infectious Diseases team. The
flag rules met the goals of providing patients with the benefit of
timely and appropriate care within the confines of critical medi-
cation resources. It is recommended that the contribution of
AMS program flags be considered in relation to the overall EHR
flag burden of a facility to avoid “alert fatigue,” especially in
COVID-19 hot spots with high patient volume (24).
In addition to diagnostic stewardship, another necessary
AMS program component is infection prevention and con-
trol. By preventing the occurrence as well as the spread of
infections, evidence-based infection prevention and control
interventions reduce the demand for antimicrobials, thereby
providing an effective antidote to inappropriate and unneces-
sary antibiotic prescriptions (25). As we confront the hurdles
surrounding implementation of universal masking and other
measures aimed at preventing SARS-CoV-2 infections, the
2016 report on the global impact of antimicrobial resistance,
commissioned by the United Kingdom, shines the spotlight
even brighter on this current crisis that needs ongoing,
urgent consideration. The report estimated that by 2050,
300 million premature deaths may occur as a result of antimi-
crobial resistance, with an anticipated loss of between 60 and
100 trillion U.S. dollars in economic output if antimicrobial
resistance is not tackled (26). The current pandemic, with its
unique challenges of diagnosis, uncertainty of the extent of
morbidity and mortality, doubts about immunity in recovery,
and lack of focused AMS program efforts, will only worsen
this issue. Now, more than ever, we have to incorporate the
lessons proposed in economist Jim O’Neill’s 2016 report,
including, but not limited to, the development of vaccines, al-
ternative therapies such as antibodies, advanced diagnostics
using advances in genomics and computer science, and con-
tinued infection prevention and control efforts (26).
DISCUSSION
As our frontline providers faced burnout in a health
care system overwhelmed by the novelty of the disease,
lack of adequate protective equipment, lack of adequate
testing (at least initially), delays in receiving laboratory-con-
firmed results, and uncertainty on how best to manage the
illness, it is understandable if there was an initial incorpora-
tion of broad-spectrum antibacterial use. As we go through
fall 2020, it is worth remembering that bacterial superinfec-
tions in past influenza seasons have presented either as ini-
tial coinfections with influenza virus or as secondary bacte-
rial infections in patients hospitalized with influenza (27).
One of the complications in COVID-19 is pulmonary dis-
tress that results in respiratory failure, acute respiratory
distress syndrome, or even ventilator-associated pneumo-
nia, all of which can be fatal (28). Previous influenza pandem-
ics have underscored the importance of treating for secondary
bacterial pneumonia, which can be fatal if untreated (16).
To meet the rigors of diagnostic stewardship, EHRs can
be designed to provide a more meaningful process for
ordering diagnostic tests (15). When implemented thought-
fully, EHRs can facilitate a culture of AMS, disease surveil-
lance (identifying potential disease spread based on moni-
toring symptoms among a population at risk), and seamless
transfers in care that successfully transition the manage-
ment of patients between facilities (29). When health care
facilities incorporate AMS program flags, regardless of facil-
ity compliance with the AMS program flags, periodic
reviews of the flags by the infectious diseases team will pro-
vide the health care community an indication of the nature
of the COVID-19 AMS program (24). What is most timely
and intelligent about this approach is its flexibility in modify-
ing flag rules based on changes in community prevalence of
COVID-19 and/or testing recommendations. It would be
prudent to adopt this approach to AMS programs in gen-
eral, adapting rules based on changes in antibiograms and/or
availability of diagnostic tests. However, incorporating alert
flags into the existing EHR may require appropriate training
of personnel serving on the infectious diseases team. In the
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upcoming influenza season, diagnostic stewardship will be
tasked with the urgent need to facilitate timely diagnosis of
influenza, COVID-19, and any bacterial pathogens either
coinfecting or causing secondary infections. If AMS is not
addressed across all health sectors, it could have devastating
consequences globally for years to come.
Effective AMS programs can dramatically improve patient
care and save more lives. We have to continue to raise aware-
ness and educate our future health care providers. Improving
antibiotic prescribing and use is a national and international
priority (26, 30). It would be prudent for health profession
schools and colleges to educate students about AMS before
they graduate or before they start their clinical rotations.
Knowing about AMS when they learn about early and appro-
priate diagnoses of infections will help inspire students to
understand the relevance of learning about the different anti-
microbials, especially as it would mean use of the appropriate
antimicrobial instead of indiscriminate use of a broad-spectrum
antibiotic. Knowing about AMS when they learn about drugs
will help the students comprehend the relevance of side effects
and/or black box warnings of certain antimicrobials. How AMS
education efforts are undertaken could depend on either guid-
ance from the IDSA or be individualized according to specific
medical school curriculum.
The current pandemic is underscoring the need to
invest a little time in educating beginner health care pro-
viders in AMS so they are aware of the challenges, threats,
and solutions. The current crisis brings renewed attention
to the need to build a heightened awareness of AMS, and
we think it is ideal that it start when students enter the
health professions.
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